These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29857775)

  • 1. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
    Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
    J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.
    Hoy SM
    Drugs; 2015 May; 75(8):879-86. PubMed ID: 25920500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
    Danese S; Siegel CA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2014 May; 39(10):1095-103. PubMed ID: 24641622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
    Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
    D'Haens GR; Kovács A; Vergauwe P; Nagy F; Molnár T; Bouhnik Y; Weiss W; Brunner H; Lavergne-Slove A; Binelli D; Di Stefano AF; Marteau P
    J Crohns Colitis; 2010 Jun; 4(2):153-60. PubMed ID: 21122499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis.
    Lichtenstein GR
    Dig Dis Sci; 2016 Feb; 61(2):358-70. PubMed ID: 26541989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience.
    Maconi G; Mezzina N; Landi S; Grillo S; Bezzio C; Bosani M; Pastorelli L; Dell'Era A; Chibbar R; Carmagnola S; Molteni P; Cassinotti A; Massari A; Ardizzone S
    United European Gastroenterol J; 2019 Nov; 7(9):1164-1170. PubMed ID: 31700629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
    Travis SP; Danese S; Kupcinskas L; Alexeeva O; D'Haens G; Gibson PR; Moro L; Jones R; Ballard ED; Masure J; Rossini M; Sandborn WJ
    Gut; 2014 Mar; 63(3):433-41. PubMed ID: 23436336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel extended release budesonide formulation for treatment of ulcerative colitis.
    Farkas K; Molnár T
    Expert Opin Pharmacother; 2014 Jan; 15(1):131-7. PubMed ID: 24219763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®
    Danese S; Hart A; Dignass A; Fiorino G; Louis E; Bonovas S; D'Haens G; Dotan I; Rogler G; Paridaens K; Peyrin-Biroulet L
    United European Gastroenterol J; 2019 Nov; 7(9):1171-1182. PubMed ID: 31700630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
    Sandborn WJ; Danese S; D'Haens G; Moro L; Jones R; Bagin R; Huang M; David Ballard E; Masure J; Travis S
    Aliment Pharmacol Ther; 2015 Mar; 41(5):409-18. PubMed ID: 25588902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Budesonide-MMX in active ulcerative colitis.
    Gionchetti P; Praticò C; Rizzello F; Calafiore A; Capozzi N; Campieri M; Calabrese C
    Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):215-22. PubMed ID: 24502535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis.
    Salice M; Rizzello F; Calabrese C; Privitera Hrustemovic H; Gionchetti P
    Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):607-613. PubMed ID: 31106602
    [No Abstract]   [Full Text] [Related]  

  • 15. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.
    Brereton N; Bodger K; Kamm MA; Hodgkins P; Yan S; Akehurst R
    J Med Econ; 2010 Mar; 13(1):148-61. PubMed ID: 20141380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis.
    Lichtenstein GR; Travis S; Danese S; D'Haens G; Moro L; Jones R; Huang M; Ballard ED; Bagin R; Hardiman Y; Collazo R; Sandborn WJ
    J Crohns Colitis; 2015 Sep; 9(9):738-46. PubMed ID: 26094251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budesonide multi-matrix system formulation for treating ulcerative colitis.
    Prantera C; Scribano ML
    Expert Opin Pharmacother; 2014 Apr; 15(6):741-3. PubMed ID: 24484392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
    Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
    Bezzio C; Festa S; Zerboni G; Papi C; Manes G; Saibeni S
    Expert Opin Drug Saf; 2018 Apr; 17(4):437-444. PubMed ID: 29473429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
    Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
    J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.